ClinicalTrials.gg
Status unknownNCT00007436Updated Jun 24, 2005

The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients

A Phase 3 interventional study of Tenofovir disoproxil fumarate in HIV Infections, sponsored by Gilead Sciences. Status unknown at 19 sites in United States. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2001), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
0 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing tenofovir in HIV Infections — 1 open to participants now, 3 under way, 1 of them phase 3. Tenofovir · HIV Infections.

Phase 3
16 of 98
none open now
Registered
6th of 98
by date
Lead sponsor
17 of 98
Gilead Sciences

Among the 98 studies testing tenofovir in HIV Infections, this one is one of 16 in phase 3, and was the 6th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 98 studies testing tenofovir in HIV Infections is open now. Recruiting first, the newest first:

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 0 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing tenofovir in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of tenofovir disoproxil fumarate (tenofovir DF) in combination with other anti-HIV drugs in patients who have participated in other tenofovir DF studies (GS-98-902 or GS-99-907), are able to tolerate the drug at different doses, and may benefit from having tenofovir DF treatment.

Read the detailed description

Patients take tenofovir DF in combination with other antiretrovirals.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Drug Therapy, Combination
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • 9-(2-phosphonylmethoxypropyl)adenine
04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Have completed another study on tenofovir DF without toxicity.
  • Are willing to use intrauterine or effective barrier methods of , both men and women, during the study and for 30 days following tenofovir DF treatment.

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Are taking drugs that may damage the kidney (nephrotoxic) including aminoglycoside antibiotics, amphotericin B, cidofovir, cisplatin, foscarnet, IV pentamidine, vancomycin, and oral or IV ganciclovir.
  • Are taking agents that affect kidney function, such as probenecid.
  • Are receiving systemic chemotherapy.
  • Are taking systemic .
  • Are taking experimental drugs except those that are approved by Gilead.
  • Are currently participating in the GS-99-908 or GS-00-912 (expanded access) studies.
  • Are pregnant or breast-feeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
06

Study locations

19 sites
  • East Bay AIDS Ctr
    Berkeley, California 94705, United States
  • Tower ID Med Associates
    Los Angeles, California 90048, United States
  • Pacific Horizons Med Group
    San Francisco, California 94115, United States
  • Harbor - UCLA Med Ctr
    Torrance, California 90502, United States
  • Univ of Colorado / Health Science Ctr
    Denver, Colorado 80262, United States
  • Physicans Home Service
    Washington, District of Columbia 20037, United States
  • Steinhart Medical Associates
    Miami, Florida 33133, United States
  • Dr Gerald Pierone Jr
    Vero Beach, Florida 32960, United States
  • Northstar Med Clinic
    Chicago, Illinois 60657, United States
  • CRI New England
    Brookline, Massachusetts 02146, United States
  • Univ of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Univ of Rochester Med Ctr
    Rochester, New York 14642, United States
  • Research & Education Group
    Portland, Oregon 97209, United States
  • Hershey Med Ctr
    Hershey, Pennsylvania 17033, United States
  • Anderson Clinical Research
    Pittsburgh, Pennsylvania 15221, United States
  • Roger Williams Med Ctr
    Providence, Rhode Island 02908, United States
  • Southwest Infectious Diseases Associates
    Dallas, Texas 75246, United States
  • Thomas Street Clinic
    Houston, Texas 77009, United States
  • Dr Philip C Craven
    Tacoma, Washington 98405, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00007436
Lead sponsor
Gilead Sciences
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2001. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion